Paolo Liberini

Brescia, 25122, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine.

Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine.

Journal: Neurology international

Published: January 11, 2023

An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor.

An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor.

Journal: European journal of neurology

Published: January 09, 2023

Photophobia and migraine outcome during treatment with galcanezumab.

Photophobia and migraine outcome during treatment with galcanezumab.

Journal: Frontiers in neurology

Published: November 02, 2022

Migraine Disability and Severity Improvement during Long-Term Treatment with Erenumab.

Migraine Disability and Severity Improvement during Long-Term Treatment with Erenumab.

Journal: European neurology

Published: August 26, 2022

Post COVID-19 vaccination headache: A clinical and epidemiological evaluation.

Post COVID-19 vaccination headache: A clinical and epidemiological evaluation.

Journal: Frontiers in pain research (Lausanne, Switzerland)

Published: July 14, 2022

CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients.

CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Published: April 14, 2022

CGRP-monoclonal antibodies and SARS-CoV-2 vaccination.

CGRP-monoclonal antibodies and SARS-CoV-2 vaccination.

Journal: Journal of neurology

Published: October 08, 2021

Migraine Monitoring in the Time of COVID-19: Triggers and Protectors During a Pandemic.

Migraine Monitoring in the Time of COVID-19: Triggers and Protectors During a Pandemic.

Journal: Pain medicine (Malden, Mass.)

Published: June 28, 2021

Erenumab Discontinuation After 12-Month Treatment: A Multicentric, Observational Real-Life Study.

Erenumab Discontinuation After 12-Month Treatment: A Multicentric, Observational Real-Life Study.

Journal: Neurology. Clinical practice

Published: January 11, 2021

Erenumab efficacy in chronic migraine and medication overuse: a real-life multicentric Italian observational study.

Erenumab efficacy in chronic migraine and medication overuse: a real-life multicentric Italian observational study.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Published: August 29, 2020

Diaphragmatic myoclonus due to SARS-CoV-2 infection.

Diaphragmatic myoclonus due to SARS-CoV-2 infection.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Published: July 12, 2020

COVID-19 impact on consecutive neurological patients admitted to the emergency department.

COVID-19 impact on consecutive neurological patients admitted to the emergency department.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: May 19, 2020

Showing 1-12 of 23

Last Updated: 09/26/2026